Source comparison
CJC-1295 vs Tesamorelin: Mechanism Comparison
Half-life 6–8 days (albumin-bound depot effect) 26–38 minutes (rapid plasma clearance) CJC-1295 allows weekly dosing; tesamorelin requires daily administration. Logistical complexity differs significantly Receptor mechanism Binds GHRH receptors and remains bou
This comparison does not assign a generated winner or score.
- Half-life
- 6–8 days (albumin-bound depot effect)
- 26–38 minutes (rapid plasma clearance)
- CJC-1295 allows weekly dosing; tesamorelin requires daily administration. Logistical complexity differs significantly
- Receptor mechanism
- Binds GHRH receptors and remains bound for days, amplifying endogenous pulses
- Binds GHRH receptors transiently, triggering immediate GH release independent of circadian rhythm
- CJC-1295 preserves physiological pulsatility; tesamorelin creates pharmacological pulse on-demand
- Dosing frequency
- 1–2× per week subcutaneous
- Daily subcutaneous (typically before bed)
- Weekly vs daily adherence requirement. Both effective, different compliance profiles
- IGF-1 elevation
- 1.5–2× baseline sustained across dosing interval
- 1.8–2.2× baseline with daily dosing (returns to baseline within 48 hours if stopped)
- Both produce measurable IGF-1 increases; CJC-1295 maintains elevation longer per dose
- Reconstitution stability
- Stable 28 days refrigerated after mixing with bacteriostatic water
- Must be used within 3 hours of reconstitution (no bacteriostatic preservative)
- CJC-1295 allows batch preparation; tesamorelin requires fresh mixing daily
- FDA approval status
- Research use only (not approved for therapeutic use)
- FDA-approved for HIV-associated lipodystrophy (brand name Egrifta)
- Tesamorelin has regulatory pathway; CJC-1295 does not